GLIADYS

Malignant glioma and brain disorders new targeted therapies

GLIADYS est accrédité par Lyonbiopôle

Identity card

Global budget: 4978 k€

Public funding: 2767 k€

Public funders: Conseil général de Rhône, FEDER Rhône-Alpes, Fonds Unique Interministériel (FUI) – DGCIS/Oséo, Grand Lyon, Oséo / BPI France (except FUI), Région Rhône-Alpes

Call for projects: FUI (FUI AAP7)

Year start: 2009

Completed project (2012-10)


Accredited by the French competitiveness cluster Lyonbiopôle


Strategic business area: Human Medicines

Application fields: Autoimmune diseases, Neurology, Oncology

Technological approaches / Keywords: Biologics, Immunotherapy

Stage of development at the beginning of the project: Discovery

Abstract

Malignant gliomas are the most frequent and lethal cancers originating in the central nervous system. GLIADYS aim at identifying new targets for yet untreated malignant gliomas with innovative technologies based on therapeutic monoclonal antibodies (MAbs).Due to the heterogeneity of malignant gliomas, several approaches targeting different antigens and/or different functional cellular mechanisms will be pursued.In vitro and in vivo anti-tumor effects of engineered MAb (agonistic, neutralizing or MAb drug conjugates) issued from iDD biotech MAb library will be assessed for tumor therapy.


Objectives

Despite recent research efforts in cancer therapy, the prognosis of patients with malignant gliomas has remained dismal. Also several axis targeting different antigens and/or different functional cellular mechanisms will be explored in the GLIADYS program. The ultimate objective of the project GLIADYS is to succeed in providing new curative treatments against malignant gliomas based on therapeutic MAbs. The partner collaboration will allow carrying out early-stage development of drugs.


Innovative assets
Highlights
Actual results
Perspectives

Innovative assets

Through Gliadys - as for example - a new innovative iDD biotech therapeutic anti DR5 MAb restored sensitivity and triggered apoptosis to eradicate cancer cells in vitro and in vivo.The Gliadys team has also succeeded in its initial objective - to set up a platform to generate prototypes of Antibody-Drug Conjugates by using iDD biotech MAb library. MAb engineering continues to show encouraging therapeutic effects against both solid tumours and haematological malignancies illustrating with the number of deals, mergers, partnerships.

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte